E-resources
Peer reviewed
Open access
-
Efficacy of immunotherapy in KRAS -mutant advanced NSCLC: A real-world study in a Chinese populationPeng, Lixiu; Guo, Jun; Kong, Li; Huang, Yong; Tang, Ning; Zhang, Juguang; Wang, Minglei; He, Xiaohan; Li, Zhenzhen; Peng, Yonggang; Wang, Zhehai; Han, Xiao
Frontiers in oncology, 01/2023, Volume: 12Journal Article
Immunotherapy has improved the clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC). However, in patients with Kirsten rat sarcoma viral oncogene homolog ( ) mutations, the superior efficacy of immunotherapy has not been elucidated and especially in real-world practice. Our study aimed to use real-world data to assess the efficacy of immunotherapy in -mutant NSCLC in a Chinese cohort. In this retrospective cohort study, we extracted the clinical, molecular, and pathologic data from the electronic health records of patients with advanced -mutant NSCLC at Shandong Cancer Hospital between January 2018 and May 2022. Furthermore, we evaluated the progression-free survival (PFS) and overall survival (OS) of the included patients. Between January 2018 and November 2020, 793 patients were identified with stage IIIB-IV NSCLC and a total of 122 patients with mutations were included in the analysis. The majority of patients were diagnosed with stage IV (82.0%) adenocarcinoma (93.4%), along with a history of smoking (57.4%). Of these, 42% of patients received anti-PD-(L)1 with or without chemotherapy (Immunotherapy-based regimens), while 58.2% of patients received chemotherapy (Chemotherapy-based regimens). The median overall survival (mOS) in this cohort was 22.9 months (95% CI: 14.1-31.7), while the median-progression-free survival (mPFS) was 9.4 months (95% CI: 6.6-12.1). Patients receiving immunotherapy-based regimens displayed better mOS than those receiving chemotherapy-based regimens (45.2 vs. 11.3 months; =1.81E-05), with no statistical difference observed in the mPFS (10.5 vs. 8.2 months; =0.706). Patients receiving immunotherapy-based regimens either in the first line ( =0.00038, =0.010, respectively) or second-line setting ( =0.010, =0.026, respectively) showed benefits in both PFS and OS. Subgroup analysis indicated that in patients having G12C or non- G12C mutant types, immunotherapy showed benefits of better OS ( =0.0037, =0.020, respectively) than chemotherapy. Moreover, in advanced NSCLCs patients with or without co-mutation the immunotherapy-based regimen achieved longer OS and PFS than chemotherapy-based regimens. In the Chinese population of patients with -mutant advanced NSCLC, immunotherapy-based regimens achieved longer OS than chemotherapy-based regimens, which was independent of first or second-line setting, as well as mutational subtypes.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.